We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Infusion Device Used for Treating Diabetes

By HospiMedica staff writers
Posted on 13 May 2008
A new infusion device uses intracellular activation therapy (iCAT) for the treatment of Type 1 and Type 2 diabetes.

The iCAT therapy treats diabetes by addressing its core problem: improper fat metabolism. More...
By treating this problem, the system is able to achieve the stabilization of diabetes complications, and in many cases, the reversal of secondary complications of both Type 1 and Type 2 diabetes. The iCAT utilizes a specially designed insulin delivery pump with proprietary algorithms, which delivers small micro-doses of insulin in a pattern that mimics the way a normal pancreas secretes insulin, which is then used by the liver. Intracellular activation therapy also uses real-time measurements of the patient's blood sugar levels and body-wide metabolic rate using a metabolic measurement cart. This data is transmitted to the pump, which automatically adjusts the next insulin dosage to stimulate a more normal metabolism. The metabolic cart also measures exhaled CO2 in the patient's breath, to determine the ‘reactivation' of normal metabolism in the patient as a result of the therapy. With normalization of liver enzyme functions, the body's cells begin to utilize glucose, something that people with diabetes cannot do normally. This treatment restores the optimum metabolism levels, which promotes healing. The iCAT system was developed by VitalCare Diabetes Treatment Centers (Carson City, NV, USA), and approved by the U.S. Food and Drug Administration (FDA).

"With the only FDA approved device delivering this treatment, we will expect to sign agreements to start the establishment of iCAT treatment centers immediately,” said Jimmy McDougald, CEO of VitalCare. "This is a major factor in the establishment of our treatment centers, as we begin to move iCAT into the commercial market.”

Vitalcare is planning to market the technology in licensed "VitalCare Diabetes Treatment Centers.” Currently, there are approximately 30 licensed iCAT clinics operating in North America, including Florida, Arizona, Utah, California, Texas, and Nevada, and anticipates having further clinics opened, which will be either company owned, joint venture, or sub-licensed affiliates, in all fifty states of the U.S. by 2010.


Related Links:
VitalCare Diabetes Treatment Centers

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.